Randomized controlled trial will evaluate both symptom progression and underlying biology

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/

Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis

Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pre-symptomatic stage offering a window for preventive treatment. However, while diagnostic tools for detecting CHR-P are well-developed, treatment options remain limited. Currently, there is no specific, indicated treatment to reduce the rate of transition to full psychosis in CHR-P patients, underlining an urgent need for developing novel interventions.

This randomized controlled trial (RCT) will assign 50 CHR-P patients (aged 14-35) to either a 12-week modified ketogenic diet or a control diet. Symptom severity will be monitored throughout the trial using the Comprehensive Assessment of At-Risk Mental States (CAARMS) assessment tool, designed specifically to assess symptom severity in young people at high risk of developing psychosis. Participants will receive support from a registered dietitian and will use glucose/ketone meter kits to track adherence to the ketogenic diet. To evaluate efficacy and tolerability, the research team will assess symptom severity, cognitive function, sleep behavior, and physical health. The trial will also follow patients’ health status for up to three years after the intervention via electronic health records to evaluate the longer-term impact.

“We see promise in ketogenic therapy as a non-stigmatizing, accessible intervention for those navigating early signs of psychosis. If effective, the diet could represent a novel tool that will allow us to intervene before psychotic onset,” said study lead Amedeo Minichino, MD DPhil CCT, Associate Professor, Honorary Consultant Psychiatrist, and Wellcome Trust Early Career Fellow at the University of Oxford. “We are hopeful that by studying the critical window that often precedes psychotic onset, we can change the long-term trajectory of mental well-being in our patients."

Since the majority of CHR-P patients do not receive antipsychotics, this will offer a unique opportunity to evaluate the clinical outcomes of ketogenic therapy as a stand-alone treatment, as well as to explore the biological mechanisms underlying both the disease and the intervention. New and growing evidence suggests that impaired brain energy metabolism, including mitochondrial dysfunction, may help us identify individuals with CHR-P who are more likely to later develop psychosis. In a subgroup of patients, the trial will measure brain energy directly using blood biomarkers and neuroimaging.

“This study is an important step forward in understanding the potential of ketogenic therapy on physical and mental health in this highly vulnerable patient group,” said Jan Ellison Baszucki, co-founder and president of Baszucki Group. “This ambitious project represents a rare opportunity to gain a deeper understanding of how ketogenic therapy could fundamentally transform the trajectory of serious mental illness in a largely medication-naive population. We are thrilled to support the research team at Oxford in this first-of-its-kind trial.”

To learn more about Baszucki Group’s ongoing funded studies, visit the Metabolic Mind website.

About Baszucki Group

Launched in 2021 by Roblox founder and Chief Executive Officer David Baszucki and best-selling author Jan Ellison Baszucki, Baszucki Group leverages grantmaking, impact investing, advocacy, storytelling, and community building to drive foundational change in science, medicine, farming, food, and environmental ecosystems. A primary focus of Baszucki Group is supporting initiatives at the intersection of metabolism, psychiatry, and neuroscience with the goal of improving mental health outcomes. To learn more about metabolic approaches to mental disorders and brain health, including ketogenic therapy, visit Metabolic Mind, a nonprofit initiative of Baszucki Group.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260521877110/en/

Baszucki Group media contact: media@baszuckigroup.org

Logo

Images

Tags

More Like This

University of Maryland Launches Innovative Clinician Training Program in Ketogenic Metabolic Therapy for Mental Health

New Bipolar Disorder Study Shows that a Ketogenic Diet Leads to Mental and Physical Health Benefits

Baszucki Group Announces Six Recipients of the Metabolic Psychiatry Scholar Award for Emerging Scientific Leaders Advancing Mental Health Innovation

Cleveland Clinic Neurological Institute and Baszucki Group Team Up to Advance Landmark Brain Study with Metabolic Health Markers

Neurocentrx Closes Seed Extension Round Including Funding from the Wellcome Trust

Ousia Pharma Secures Substantial Seed Financing Led by Omega Funds to Advance Groundbreaking Obesity Treatment

Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002

B.More Collaborator, Dr. Michael Bogenschutz, Awarded NIAAA Grant for Psilocybin in Alcohol Use Disorder Trial at NYU and Silver Hill Hospital